demonstrated that by disrupting the VEGF/VEGFR-2 axis with anti-VEGF antibodies to “normalize” the tumor vascular system and using it in conjunction with ACT, antibody therapy significantly promotes immune cell infiltration. The gene discussed is KDR; the disease is neoplasm.